Dr. Reddy's Laboratories
148 hedge funds and large institutions have $866M invested in Dr. Reddy's Laboratories in 2022 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 51 increasing their positions, 45 reducing their positions, and 18 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
28% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 18
13% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 45
1% more funds holding
Funds holding: 146 → 148 (+2)
2.99% less ownership
Funds ownership: 49.9% → 46.91% (-3%)
6% less capital invested
Capital invested by funds: $924M → $866M (-$57.3M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $222K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$27.5M |
| 2 |
GQG Partners
Ft. Lauderdale,
Florida
|
+$9.64M |
| 3 |
Renaissance Technologies
New York
|
+$6.82M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$5.68M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$3.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$33M |
| 2 |
JP Morgan Chase
New York
|
-$12.1M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
-$10.5M |
| 4 |
State Street
Boston,
Massachusetts
|
-$7.46M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$6.94M |
RDY Hedge Fund Activity: Q2 2022 in Review
148 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Dr. Reddy's Laboratories (RDY) for Q2 2022, worth a combined $866M — down 6.2% from $924M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new RDY positions and 18 closed out — a net gain of 5 holders — while 51 added to existing stakes and 45 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $27.5M. The largest seller was Millennium Management, cutting an estimated $33M.
- 148 institutional investors held Dr. Reddy's Laboratories (RDY) as of Q2 2022, up from 146 in Q1 2022.
- Funds reported $866M of Dr. Reddy's Laboratories stock for Q2 2022, down 6.2% quarter-over-quarter.
- 23 funds opened new Dr. Reddy's Laboratories positions in Q2 2022 and 18 closed out, a net change of +5 holders.
- The largest Dr. Reddy's Laboratories buyer in Q2 2022 was Morgan Stanley, an estimated $27.5M added.
- The largest Dr. Reddy's Laboratories seller in Q2 2022 was Millennium Management, an estimated $33M sold.
Based on aggregated 13F filings for Q2 2022.